BOSTON, MA – February 13, 2024 via PRNewsWire (Link) Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA approved medical device proven to significantly reduce reherniations and reoperations following lumbar discectomy surgery, today announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors. “We are thrilled to welcome these two […]
Read moreIn the News
Intrinsic Therapeutics, Inc. Announces Results from Post Market Study Confirming Benefits of Barricaid Annular Closure Implant
Press ReleaseBOSTON, MA – June 28, 2023 via PRNewsWire (Link) Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, today has announced the publication of results from a post-market study in the Cureus Journal of Medical Science, showing that the use of Barricaid in high-risk patients results in significantly […]
Read more
Intrinsic Therapeutics, Inc. Announces Positive Coverage Policy by Cigna Healthcare for Barricaid Bone-Anchored Annular Closure Device
Press ReleaseBOSTON, MA – June 21, 2023 via PRNewsWire (Link) Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device. Cigna Healthcare represents one of the five largest commercial payors in the […]
Read more
Barricaid in the News: New Surgical Device Helping Patients With Herniated Disc
CHARLOTTE, N.C. — A new medical device is helping patients recover more efficiently from spinal injuries while also reducing the chance they return to the hospital. What You Need To Know Austin Rabah needed a discectomy after a sports injury, which is a spinal surgery on a herniated disc A herniated disc is when fluid […]
Read more
Intrinsic announces publication of paper detailing the usage of annular closure with Barricaid in conjunction with tubular minimally invasive discectomy
Based on retrospective analysis of 60 patients treated with the Barricaid annular closure device, this analysis, titled: Implantation of a bone-anchored annular closure device in conjunction with tubular minimally invasive discectomy for lumbar disc herniation: a retrospective study examined the safety and viability of an annular closure device in limiting reherniation and reoperation in a […]
Read more
Five Year Follow-Up of Level-1 Spine Study Confirms Long-Term Benefits of Barricaid® Disc Closure Device
NewsBOSTON, MA – January 25, 2022 via PRNewsWire (Link) Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, today announced the publication in JAMA Network Open of the five-year follow-up results from its landmark clinical trial demonstrating that the use of Barricaid following discectomy is superior to treating […]
Read more
Barricaid Webinars – Make the First Spine Surgery the Last
Barricaid is a proven technology that reduces reoperations for reherniations by 81% in a well-defined patient population. Learn about the clinical efficacy and superiority RCT for Barricaid from Oscar Yeh, Chief Operating Officer of Intrinsic Therapeutics, Inc in this payor-focused webinar, recorded on 12/9/21. For full benefit/risk information, please visit www.barricaid.com/instructions. PPT22 Rev. A
Read more
Lumbar Disc Herniation: What Stops It From Happening Again?
NewsThousands of people every year in the United States herniate spinal discs. The spine is cushioned at each bony level by an intervertebral disc, which acts as a shock absorber. When one of these discs ruptures or herniates, it can lead to a painful feeling in the back as well as radiating pain into the […]
Read more
Barricaid selected as case study for evaluating strength of evidence for Health Technology Assessments
Barricaid was selected as a case study in evaluating strength of evidence for Health Technology Assessments due to its superior clinical outcomes, favorable health economics, and level 1 RCT data. Read the full article here: https://www.cureus.com/articles/64017-towards-a-more-simplified-approach-for-evaluating-strength-of-evidence-in-health-technology-assessments
Read more
Clinical Evidence Supports Medical Necessity of Annular Repair Using Barricaid
Barricaid, the only FDA approved device proven to reduce disc reherniation, has reachedanother significant milestone. On June 23, 2021, Hayes published a comprehensive HealthTechnology Assessment (HTA) which complements the previously published positive HTAby ECRI. The Hayes assessment confirms that the Barricaid technology is founded upon asubstantial body of clinical and economic evidence. Implantation of Barricaid […]
Read more